Image source: Exact Sciences.
What: Following the release of new guidance for colon cancer screening issued by the U.S. Preventative Services Task Force (USPSTF), shares in Exact Sciences (NASDAQ: EXAS) skyrocketed by 83.4% last month, according to S&P Global Market Intelligence.